top
Search terms
Results 1 - 8 of 8 - ordered by :
Ehjcvp

Using a Cox proportional hazard model adjusting for baseline characteristics, use of apixaban [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.610.80, P0.001] and dabigatran (HR 0.74, 95% CI ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sigrun Halvorsen, Waleed Ghanima, Ingunn Fride Tvete, Cecilie Hoxmark, PÃ¥l Falck, Oddvar Solli, Christian Jonasson

Date : 27/09/2016
Ehjcvp

Abstract Aims To determine whether risk factor changes over 6 years were associated with the incidence of atrial fibrillation (AF) among middle-aged men in the Malmö Preventive Project (MPP) ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Linda S.B. Johnson, Tord Juhlin, Gunnar Engström, Peter M. Nilsson

Date : 01/04/2016
Ehjcvp

Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Anders Sahlén, Christoph Varenhorst, Bo Lagerqvist, Henrik Renlund, Lars Wallentin, Stefan K. James, Tomas Jernberg

Date : 01/01/2016 Item size : 280123 bytes
Ehjcvp

Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events Introduction Cardiovascular disease (CVD) is widespread, ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Laura A. Fortuna, Pamala A. Pawloski, Emily D. Parker, Nicole K. Trower, Thomas E. Kottke

Date : 01/01/2016 Item size : 263457 bytes
Ehjcvp

Methods and results In this observational study, 5426 Chinese AF patients (77.7 ± 10.7 years, female: 53.1%) with a CHA2DS2-VASc score of 1 were included in the final analysis: of which, 3832 ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Pak-Hei Chan, Wen-Hua Li, Jo-Jo Hai, Koon-Ho Chan, Hung-Fat Tse, Bernard Man-Yung Cheung, Esther W. Chan, Ian C.K. Wong, ...

Date : 01/10/2015
Ehjcvp

Serum potassiumHeart failure after myocardial infarctionMortalityIntroduction Heart failure is a common and serious complication of acute myocardial infarction (MI), and frequently requires treatment ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Maria Lukács Krogager, Lotti Eggers-Kaas, Kristian Aasbjerg, Rikke Nørmark Mortensen, Lars Køber, Gunnar Gislason, ...

Date : 01/10/2015
Ehjcvp

A recently published postmarketing study has shown that dabigatran causes a significantly higher risk of extracranial bleeding than VKAs in clinical practice.3 It was also found that NVAF patients ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Herbert J.A. Rolden, Janneke P.C. Grutters, Gert Jan van der Wilt, Angela H.E.M. Maas

Date : 01/07/2015
Ehjcvp

At age 40, the associated lifetime risk of developing coronary heart disease is 48.6% among men and 31.7% among women.1 Despite advances in the field of non-invasive coronary artery testing and ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Mads E. Jørgensen, Charlotte Andersson, Anne-Marie Schjerning Olsen, Knud Juel, Poul Erik Mortensen, Erik Jørgensen, ...

Date : 01/07/2015